keyword
MENU ▼
Read by QxMD icon Read
search

breast cancer pathology

keyword
https://read.qxmd.com/read/30771221/mortality-after-breast-cancer-as-a-function-of-time-since-diagnosis-by-estrogen-receptor-status-and-age-at-diagnosis
#1
Harindra Jayasekara, Robert J MacInnis, James A Chamberlain, Gillian S Dite, Nicole M Leoce, James G Dowty, Adrian Bickerstaffe, Aung Ko Win, Roger L Milne, Graham G Giles, Mary Beth Terry, Diana M Eccles, Melissa C Southey, John L Hopper
Our aim was to estimate how long-term mortality following breast cancer diagnosis depends on age at diagnosis, tumor estrogen receptor (ER) status, and the time already survived. We used the population-based Australian Breast Cancer Family Study which followed-up 1,196 women enrolled during 1992-99 when aged <60 years at diagnosis with a first primary invasive breast cancer, over-sampled for younger ages at diagnosis, for whom tumor pathology features and ER status were measured. There were 375 deaths (median follow-up=15...
February 16, 2019: International Journal of Cancer. Journal International du Cancer
https://read.qxmd.com/read/30771195/esophageal-metastasis-of-breast-cancer-during-endocrine-therapy-for-pleural-dissemination-21-years-after-breast-surgery-a-case-report
#2
Masuyo Miyake, Akimitsu Yamada, Kentaro Miyake, Itaru Endo
BACKGROUND: The esophageal metastasis of breast cancer is rare. Moreover, it is extremely unusual for patients to experience the symptoms of esophageal metastasis during their lifetimes. We present a case of dysphagia caused by esophageal metastasis after a long interval following a primary mastectomy. CASE PRESENTATION: A 77-year-old woman with a history of heterochronous bilateral breast cancer and under treatment for pleural dissemination recurrence originating from right breast cancer complained of dysphagia...
February 15, 2019: Surgical Case Reports
https://read.qxmd.com/read/30770770/imprint-of-parity-and-age-at-first-pregnancy-on-the-genomic-landscape-of-subsequent-breast-cancer
#3
Bastien Nguyen, David Venet, Matteo Lambertini, Christine Desmedt, Roberto Salgado, Hugo Mark Horlings, Françoise Rothé, Christos Sotiriou
BACKGROUND: Although parity and age at first pregnancy are among the most known extrinsic factors that modulate breast cancer risk, their impact on the biology of subsequent breast cancer has never been explored in depth. Recent data suggest that pregnancy-induced tumor protection is different according to breast cancer subtypes, with parity and young age at first pregnancy being associated with a marked reduction in the risk of developing luminal subtype but not triple negative breast cancer...
February 15, 2019: Breast Cancer Research: BCR
https://read.qxmd.com/read/30767161/elevated-expression-of-gnas-promotes-breast-cancer-cell-proliferation-and-migration-via-the-pi3k-akt-snail1-e-cadherin-axis
#4
X Jin, L Zhu, Z Cui, J Tang, M Xie, G Ren
PURPOSE: Although it has been well established that G protein plays pivotal roles in physiologic or pathologic conditions, including cancer formation, its role in breast cancer, especially specific subunits, remains largely unknown. Our work aimed to evaluate the correlation of the G protein alpha subunit (GNAS) with breast cancer and to investigate the underlying molecular mechanism. METHODS: The expression of GNAS was determined by breast tumor tissue microarray of 150 patients with complete follow-up information...
February 14, 2019: Clinical & Translational Oncology
https://read.qxmd.com/read/30765238/significance-of-serum-survivin-and-31g-c-gene-polymorphism-in-the-early-diagnosis-of-breast-cancer-in-egypt
#5
Tarek M K Motawi, Nadia I Zakhary, Hebatallah A Darwish, Hassan M Abdalla, Samer A Tadros
BACKGROUND: Breast cancer is one of the most relevant malignancies among women. Molecular abnormalities in promotor region of survivin gene may account for overexpression of survivin and increased breast cancer risk. This study aimed to explore the potential association between survivin promotor gene -31G/C single nucleotide polymorphism (rs9904341) and its serum level alteration on one hand, and the risk of breast cancer in Egyptian patients on the other hand. It also aimed to assess the usefulness of survivin as an early noninvasive diagnostic biomarker and in breast cancer staging...
January 6, 2019: Clinical Breast Cancer
https://read.qxmd.com/read/30764626/is-there-a-benefit-of-her2-positive-breast-cancer-subtype-determination-in-clinical-practice
#6
I Kolářová, J Vaňásek, K Odrážka, L Dušek, Z Šinkorová, A Hlávka, J Štuk, J Stejskal, D Dvořáková, L Sákra, J Mergancová, Z Vilasová
BACKGROUND: Breast cancer (BC) with increased expression of human epidermal growth factor receptor 2 with tyrosine kinase activity (HER2+) is a clinically and bio-logically heterogeneous dis-ease. In terms of gene expression, there are four major molecular subtypes - Luminal A, Luminal B, HER2-enriched (HER2-E), and Basal-like. The most common subtype is HER2-E (50-&#8202;60%). In hormone-dependent (HR+) HER2-positive tumors, the subgroup HER2-E represents 40-&#8202;50% of cases; others are luminal A and B subtypes...
2019: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
https://read.qxmd.com/read/30763338/tailored-neoadjuvant-epirubicin-cyclophosphamide-and-nanoparticle-albumin-bound-paclitaxel-for-breast-cancer-the-phase-ii-neonab-trial-clinical-outcomes-and-molecular-determinants-of-response
#7
Caitlin Murphy, Andrea Muscat, David Ashley, Violet Mukaro, Linda West, Yang Liao, David Chisanga, Wei Shi, Ian Collins, Sally Baron-Hay, Sujata Patil, Geoffrey Lindeman, Mustafa Khasraw
BACKGROUND: This study evaluated the feasibility of achieving high response rates in stage II or III breast cancer by tailoring neoadjuvant therapy using clinical and histopathological features and the Oncotype DX Breast Recurrence Score. Genomic determinants of response and resistance were also explored. PATIENTS AND OUTCOME MEASURES: Fifty-one patients were enrolled. The primary cohort comprised 40 patients: 15 human epidermal growth factor receptor type 2 (HER2)-amplified; 15 triple-negative (TNBC); and ten hormone receptor (HR)-positive, HER2-non-amplified tumours; with recurrence scores ≥25...
2019: PloS One
https://read.qxmd.com/read/30762525/high-quality-immunohistochemical-stains-through-computational-assay-parameter-optimization
#8
Nuri Murat Arar, Pushpak Pati, Aditya Kashyap, Anna Fomitcheva Khartchenko, Orcun Goksel, Govind V Kaigala, Maria Gabrani
Accurate profiling of tumors using immunohistochemistry (IHC) is essential in cancer diagnosis. The inferences drawn from IHC-stained images depend to a great extent on the quality of immunostaining, which is in turn affected strongly by assay parameters. To optimize assay parameters, the available tissue sample is often limited. Moreover, with current practices in pathology, exploring the entire assay parameter space is not feasible. Thus, the evaluation of IHC stained slides is conventionally a subjective task, in which diagnoses are commonly drawn on images that are suboptimal...
February 13, 2019: IEEE Transactions on Bio-medical Engineering
https://read.qxmd.com/read/30761270/eya2-correlates-with-clinico-pathological-features-of-breast-cancer-promotes-tumor-proliferation-and-predicts-poor-survival
#9
Hanxiao Xu, Ying Jiao, Ming Yi, Weiheng Zhao, Kongming Wu
Eyes absent homolog 2 (EYA2), a transcriptional activator, is pivotal for organ development, but aberrant regulation of EYA2 has been reported in multiple human tumors. However, the role of EYA2 in breast cancer is still lack of full understanding. To explore the biological significance of EYA2 in breast cancer, we conducted data analysis on public breast cancer datasets, and performed immunohistochemistry (IHC) analysis, colony-forming unit assays, EdU assay, western blotting, and immunofluorescence (IF). Meta-analysis showed that EYA2 mRNA expression was correlated with tumor grade, the status of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)...
2019: Frontiers in Oncology
https://read.qxmd.com/read/30760859/ductal-carcinoma-in-situ-of-the-breast-an-update-for-the-pathologist-in-the-era-of-individualized-risk-assessment-and-tailored-therapies
#10
REVIEW
Wedad M Hanna, Carlos Parra-Herran, Fang-I Lu, Elzbieta Slodkowska, Eileen Rakovitch, Sharon Nofech-Mozes
Ductal carcinoma in situ (DCIS) is a neoplastic proliferation of mammary ductal epithelial cells confined to the ductal-lobular system, and a non-obligate precursor of invasive disease. While there has been a significant increase in the diagnosis of DCIS in recent years due to uptake of mammography screening, there has been little change in the rate of invasive recurrence, indicating that a large proportion of patients diagnosed with DCIS will never develop invasive disease. The main issue for clinicians is how to reliably predict the prognosis of DCIS in order to individualize patient treatment, especially as treatment ranges from surveillance only, breast-conserving surgery only, to breast-conserving surgery plus radiotherapy and/or hormonal therapy, and mastectomy with or without radiotherapy...
February 13, 2019: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://read.qxmd.com/read/30760580/platelet-decoys-inhibit-thrombosis-and-prevent-metastatic-tumor-formation-in-preclinical-models
#11
Anne-Laure Papa, Amanda Jiang, Netanel Korin, Michelle B Chen, Erin T Langan, Anna Waterhouse, Emma Nash, Jildaz Caroff, Amanda Graveline, Andyna Vernet, Akiko Mammoto, Tadanori Mammoto, Abhishek Jain, Roger D Kamm, Matthew J Gounis, Donald E Ingber
Platelets are crucial for normal hemostasis; however, their hyperactivation also contributes to many potentially lethal pathologies including myocardial infarction, stroke, and cancer. We hypothesized that modified platelets lacking their aggregation and activation capacity could act as reversible inhibitors of platelet activation cascades. Here, we describe the development of detergent-extracted human modified platelets (platelet decoys) that retained platelet binding functions but were incapable of functional activation and aggregation...
February 13, 2019: Science Translational Medicine
https://read.qxmd.com/read/30759193/comparison-of-six-breast-cancer-classifiers-using-qpcr
#12
Evi Berchtold, Martina Vetter, Melanie Gündert, Gergely Csaba, Christine Fathke, Susanne E Ulbrich, Christoph Thomssen, Ralf Zimmer, Eva J Kantelhardt
Motivation: Several gene expression based risk scores and subtype classifiers for breast cancer were developed to distinguish high and low risk patients. Evaluating the performance of these classifiers helps to decide which classifiers should be used in clinical practice for personal therapeutic recommendations. So far, studies that compared multiple classifiers in large independent patient cohorts mostly used microarray measurements. qPCR based classifiers were not included in the comparison or had to be adapted to the different experimental platforms...
February 13, 2019: Bioinformatics
https://read.qxmd.com/read/30756285/real-world-data-on-discordance-between-estrogen-progesterone-and-her2-receptor-expression-on-diagnostic-tumor-biopsy-versus-tumor-resection-material
#13
A M Sofie Berghuis, Carolien H M van Deurzen, Hendrik Koffijberg, Leon W M M Terstappen, Stefan Sleijfer, Maarten J IJzerman
PURPOSE: The estrogen (ER), progesterone (PR), and HER2 status are essential in guiding treatment decisions in breast cancer patients. In daily life, the ER/PR/HER2 status is expected to be commonly tested twice, i.e., at diagnosis using material from tumor needle biopsies, and after tumor resection using full tumor tissue material. This study explored the discordance of ER/PR/HER2 between tumor needle biopsies and full tumor resection material using real-world patient-level data from Dutch breast cancer patients...
February 13, 2019: Breast Cancer Research and Treatment
https://read.qxmd.com/read/30755102/microrna-143-is-associated-with-pathological-complete-response-and-regulates-multiple-signaling-proteins-in-breast-cancer
#14
Raúl García-Vázquez, Laurence A Marchat, Erika Ruíz-García, Horacio Astudillo-de la Vega, Abelardo Meneses-García, Claudia Arce-Salinas, Enrique Bargallo-Rocha, Ángeles Carlos-Reyes, José Sullivan López-González, Carlos Pérez-Plasencia, Rosalío Ramos-Payán, Maribel Aguilar-Medina, César López-Camarillo
Almost 55% to 80% of patients with breast cancer have an unfavorable pathological complete response to chemotherapy. MicroRNAs are small noncoding RNAs involved in cancer progression; however, their utility as predictors of pathological complete response to neoadjuvant chemotherapy is unclear. Here, we investigated if miR-143 could discriminate between pathological complete response and no-polymerase chain reaction of patients with locally advanced triple negative breast cancer that have received a fluorouracil-cisplatin/paclitaxel-based neoadjuvant treatment...
January 1, 2019: Technology in Cancer Research & Treatment
https://read.qxmd.com/read/30754960/dietary-patterns-nutrition-and-risk-of-breast-cancer-case-control-study-in-the-west-of-iran
#15
Behjat Marzbani, Javad Nazari, Saeed Amini, Farid Najafi, Mehdi Moradinazar, Behnaz Marzbani, Sara Shahabadi, Mahin Amini, Yahya Pasdar, Ebrahim Shakiba
Objectives: Unhealthy dietary patterns are the most important changeable risk factors for breast cancer. The aim is to assess the relation between dietary patterns and risk of breast cancer among under 50 women in the west of Iran. Methods: All under 50 years old women with positive pathology of breast cancer between 2013-2015 who were referred to the oncology clinics in the west of Iran were selected as the cases (212 persons) and 408 under 50 years old women referred to the other outpatient clinics who were without breast or other cancers at the time of study and two years later were selected as the control group...
January 24, 2019: Epidemiology and Health
https://read.qxmd.com/read/30753543/ki-67-labeling-index-as-a-predictor-of-response-to-neoadjuvant-chemotherapy-in-breast-cancer
#16
Parveen Jain, Dinesh Chandra Doval, Ullas Batra, Pankaj Goyal, Sneha Jatan Bothra, Chaturbhuj Agarwal, Dutta Kumardeep Choudhary, Abhishek Yadav, Venkata Pradeep Babu Koyalla, Mansi Sharma, Prashanta Dash, Vineet Talwar
Aims: To investigate Ki-67 index with regard to its ability to predict achievement of pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) in breast cancer patient. Material and methods: It was a prospective observational study, conducted in Department of Medical Oncology, Rajiv Gandhi Cancer Institute & Research Center (RGCIRC), New Delhi from February 2014 to March 2016. A total of 134 patients with Stage II/III breast cancer who underwent NACT followed by surgery at our center were enrolled and analyzed...
February 12, 2019: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/30753274/the-immune-profile-of-small-her2-positive-breast-cancers-a-secondary-analysis-from-the-apt-trial
#17
R Barroso-Sousa, W T Barry, H Guo, D Dillon, Y B Tan, K Fuhrman, W Osmani, A Getz, M Baltay, C Dang, D Yardley, B Moy, P K Marcom, E A Mittendorf, I E Krop, E P Winer, S M Tolaney
Background: Previous data suggest that the immune microenvironment plays a critical role in HER2-positive breast cancer, however there is little known about the immune profiles of small HER2-positive tumors. In this study we aimed to characterize the immune microenvironment of small HER2-positive breast cancers included in the APT trial, and to correlate the immune markers with pathological and molecular tumor characteristics. Patients and Methods: The APT trial was a multicenter, single-arm phase II study of paclitaxel and trastuzumab in patients with node-negative HER2-positive breast cancer...
February 7, 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/30747329/identification-of-3q-oncogene-sec62-as-a-marker-for-distant-metastasis-and-poor-clinical-outcome-in-invasive-ductal-breast-cancer
#18
Ferenc Zoltan Takacs, Julia Caroline Radosa, Maximilian Linxweiler, Mariz Kasoha, Rainer M Bohle, Florian Bochen, Clara Unger, Erich-Franz Solomayer, Bernard Schick, Ingolf Juhasz-Böss
PURPOSE: In previous studies, we have shown that SEC62 has an essential function in cell migration, epithelial-to-mesenchymal transition, and endoplasmic reticulum stress tolerance of cancer cells. SEC62 expression correlated with distant and lymph node metastasis and poor outcome in different cancer entities. In this initial study, we investigated SEC62 expression and its possible role as a prognostic and predictive biomarker in breast cancer (BC). METHODS: Formalin-fixed, paraffin-embedded tissue samples of 53 BC patients were analyzed by immunohistochemistry...
February 12, 2019: Archives of Gynecology and Obstetrics
https://read.qxmd.com/read/30746706/molecular-comparison-of-interval-and-screen-detected-breast-cancers
#19
Dane Cheasley, Na Li, Simone M Rowley, Kenneth Elder, G Bruce Mann, Sherene Loi, Peter Savas, David L Goode, Tanjina Kader, Magnus Zethoven, Tim Semple, Stephen B Fox, Jia-Min Pang, David Byrne, Lisa Devereux, Carolyn Nickson, Pietro Procopio, Grant Lee, Siobhan Hughes, Hugo Saunders, Kenji M Fujihara, Keilly Kuykhoven, Jacquie Connaughton, Paul A James, Kylie L Gorringe, Ian G Campbell
Breast cancer (BC) diagnosed after a negative mammogram but prior to the next screening episode is termed an "interval breast cancer" (IBC). Understanding the molecular differences between IBC and screen-detected breast cancers (SDBC) could improve mammographic screening and management options. Therefore, we assessed both germline and somatic genomic aberrations in a prospective cohort. Utilizing the Lifepool cohort of >54,000 women attending mammographic screening programs, 930 BC cases with screening status were identified (726 SDBC and 204 IBC)...
February 11, 2019: Journal of Pathology
https://read.qxmd.com/read/30745320/the-role-of-ackr3-in-breast-lung-and-brain-cancer
#20
Maria Neves, Amos Fumagalli, Jelle van den Bor, Philippe Marin, Martine J Smit, Federico Mayor
Recent reports regarding the significance of chemokine receptors in disease have put a spotlight on ACKR3. This atypical chemokine receptor is overexpressed in numerous cancer types and has been involved in the modulation of tumour cell proliferation and migration, tumour angiogenesis or resistance to drugs, thus contributing to cancer progression and metastasis occurrence. Here we focus on the clinical significance and potential mechanisms underlying the pathological role of ACKR3 in breast, lung and brain cancer and discuss its possible relevance as prognostic factor and potential therapeutic target in these contexts...
February 11, 2019: Molecular Pharmacology
keyword
keyword
158315
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"